OncoMatch/Clinical Trials/NCT06627738
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
Is NCT06627738 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for carcinoma, non-small-cell lung.
This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in patients with locally advanced non-small cell lung carcinoma (NSCLC), with an interim analysis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR positive mutation
Positive EGFR mutation
Disease stage
Required: Stage III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — induction (2 cycles) and concomitant (at least 2 cycles) with radiotherapy
2 cycles of induction chemotherapy (platinium-based doublet) and then at least 40 Gy of irradiation in combination with at least 2 cycles of concomitant chemotherapy (platinium-based doublet)
Must have received: radiation therapy — at least 40 Gy, with chemotherapy
at least 40 Gy of irradiation in combination with at least 2 cycles of concomitant chemotherapy (platinium-based doublet)
Lab requirements
Cardiac function
No exercise-induced dyspnea associated with heart failure ≥ NYHA III; no coronary syndrome or heart failure in last 3 months
Exercise-induced dyspnea associated with heart failure equal to or greater than stage III of the New York Heart Association (NYHA) classification [excluded]; Coronary syndrome or heart failure in the last three months [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06627738 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy and radiation therapy.
Are patients with EGFR alterations eligible?
No. EGFR positive mutation is an exclusion criterion.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages